McKesson Cash Flow from Investing Activities 2010-2024 | MCK

McKesson annual/quarterly cash flow from investing activities history and growth rate from 2010 to 2024. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
  • McKesson cash flow from investing activities for the quarter ending March 31, 2024 was $-1.072B, a 97.79% increase year-over-year.
  • McKesson cash flow from investing activities for the twelve months ending March 31, 2024 was $-2.031B, a 196.5% increase year-over-year.
  • McKesson annual cash flow from investing activities for 2024 was $-1.072B, a 97.79% increase from 2023.
  • McKesson annual cash flow from investing activities for 2023 was $-0.542B, a 508.99% increase from 2022.
  • McKesson annual cash flow from investing activities for 2022 was $-0.089B, a 78.55% decline from 2021.
McKesson Annual Cash Flow Investing
(Millions of US $)
2024 $-1,072
2023 $-542
2022 $-89
2021 $-415
2020 $-579
2019 $-1,381
2018 $-2,993
2017 $-3,269
2016 $-1,557
2015 $-677
2014 $-5,046
2013 $-2,209
2012 $-1,502
2011 $-624
2010 $-309
2009 $-727
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $74.038B $308.951B
McKesson Corporation is a health care services and information technology company. McKesson operates through two segments: The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions. per segment realignment, McKesson reported revenues through four segments: U.S. Pharmaceutical and Specialty Solutions, Internation, Medical-Surgical Solutions and Prescription Technology Solutions.
Stock Name Country Market Cap PE Ratio
Becton Dickinson (BDX) United States $67.041B 18.97
Cardinal Health (CAH) United States $24.179B 13.83
West Pharmaceutical Services (WST) United States $24.141B 43.26
Align Technology (ALGN) United States $19.363B 37.38
Cooper (COO) United States $18.745B 27.70
Labcorp (LH) United States $16.431B 14.14
Henry Schein (HSIC) United States $8.879B 15.80
DENTSPLY SIRONA (XRAY) United States $5.816B 15.06
Merit Medical Systems (MMSI) United States $4.715B 25.84
CONMED (CNMD) United States $2.354B 21.35
Patterson (PDCO) United States $2.203B 10.55
STAAR Surgical (STAA) United States $2.040B 78.36
Atrion (ATRI) United States $0.810B 43.26
Lifevantage (LFVN) United States $0.097B 12.48
Pro-Dex (PDEX) United States $0.067B 33.98
Biolase (BIOL) United States $0.006B 0.00